Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex

Cancer Cell

Volumn 5, Issue 1, 2004, Pages 91-102

  Lepourcelet, Maina ^a,b   Chen, Ying Nan P ^c   France, Dennis S ^c   Wang, Huisheng ^c   Crews, Phillip ^d   Petersen, Frank ^c   Bruseo, Charles ^c,e   Wood, Alexander W ^c   Shivdasani, Ramesh A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; T CELL FACTOR PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; MOLECULAR DYNAMICS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; XENOPUS;

ANIMALIA;

EID: 1642512639     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00334-9     Document Type: Article

References (68)

1. Anderson C.B., Neufeld K.L., White R.L. Subcellular distribution of Wnt pathway proteins in normal and neoplastic colon. Proc. Natl. Acad. Sci. USA. 99:2002;8683-8688.
2. Andrews N.C., Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:1991;2499.
3. Arkin M.R., Randal M., DeLano W.L., Hyde J., Luong T.N., Oslob J.D., Raphael D.R., Taylor L., Wang J., McDowell R.S.et al. Binding of small molecules to an adaptive protein-protein interface. Proc. Natl. Acad. Sci. USA. 100:2003;1603-1608.
4. Assert R., Kotter R., Bisping G., Scheppach W., Stahlnecker E., Muller K.M., Dusel G., Schatz H., Pfeiffer A. Anti-proliferative activity of protein kinase C in apical compartments of human colonic crypts. evidence for a less activated protein kinase C in small adenomas Int. J. Cancer. 80:1999;47-53.
5. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y.et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA. 96:1999;5698-5703.
6. Batlle E., Henderson J.T., Beghtel H., van den Born M.M., Sancho E., Huls G., Meeldijk J., Robertson J., van de Wetering M., Pawson T.et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell. 111:2002;251-263.
7. Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., Vogt P.K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA. 99:2002;3830-3835.
8. Brannon M., Gomperts M., Sumoy L., Moon R.T., Kimelman D. A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus. Genes Dev. 11:1997;2359-2370.
9. Chan T.A., Wang Z., Dang L.H., Vogelstein B., Kinzler K.W. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc. Natl. Acad. Sci. USA. 99:2002;8265-8270.
10. Chen R.H., Ding W.V., McCormick F. Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J. Biol. Chem. 275:2000;17894-17899.
11. Chen J.K., Taipale J., Young K.E., Maiti T., Beachy P.A. Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA. 99:2002;14071-14076.
12. Chesire D.R., Ewing C.M., Gage W.R., Isaacs W.B. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene. 21:2002;2679-2694.
13. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
14. Cobrinik D., Whyte P., Peeper D.S., Jacks T., Weinberg R.A. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7:1993;2392-2404.
15. Cochran A.G. Protein-protein interfaces. mimics and inhibitors Curr. Opin. Chem. Biol. 5:2001;654-659.
16. Cook D., Fry M.J., Hughes K., Sumathipala R., Woodgett J.R., Dale T.C. Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J. 15:1996;4526-4536.
17. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A.et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA. 95:1998;8847-8851.
18. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S.et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037.
19. Drummond D.R., McCrae M.A., Colman A. Stability and movement of mRNAs and their encoded proteins in Xenopus oocytes. J. Cell Biol. 100:1985;1148-1156.
20. Eklof Spink K., Fridman S.G., Weis W.I. Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex. EMBO J. 20:2001;6203-6212.
21. Fasolini M., Wu X., Flocco M., Trosset J.Y., Oppermann U., Knapp S. Hotspots in Tcf4 for the interaction with beta-catenin. J. Biol. Chem. 278:2003;21092-21098.
22. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell. 4:1999;199-207.
23. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15:2001;3249-3262.
24. Gokmen-Polar Y., Murray N.R., Velasco M.A., Gatalica Z., Fields A.P. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res. 61:2001;1375-1381.
25. Graham T.A., Weaver C., Mao F., Kimelman D., Xu W. Crystal structure of a beta-catenin/Tcf complex. Cell. 103:2000;885-896.
26. Graham T.A., Ferkey D.M., Mao F., Kimelman D., Xu W. Tcf4 can specifically recognize beta-catenin using alternative conformations. Nat. Struct. Biol. 8:2001;1048-1052.
27. Green D.W., Roh H., Pippin J.A., Drebin J.A. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J. Surg. Res. 101:2001;16-20.
28. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science. 281:1998;1509-1512.
29. Huber A.H., Weis W.I. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell. 105:2001;391-402.
30. Ilyas M., Tomlinson I.P., Rowan A., Pignatelli M., Bodmer W.F. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. USA. 94:1997;10330-10334.
31. Jimenez C., Quinoa E., Crews P. Novel marine sponge alkaloids 3. B-carbolinium salts from Fascaplysinopsis reticulata. Tetrahedron Lett. 32:1991;1843-1846.
32. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
33. Knapp S., Zamai M., Volpi D., Nardese V., Avanzi N., Breton J., Plyte S., Flocco M., Marconi M., Isacchi A.et al. Thermodynamics of the high-affinity interaction of TCF4 with beta-catenin. J. Mol. Biol. 306:2001;1179-1189.
34. Kobayashi E., Nakano H., Morimoto M., Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:1989;548-553.
35. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science. 275:1997;1784-1787.
36. Korinek V., Barker N., Moerer P., van Donselaar E., Huls G., Peters P.J., Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat. Genet. 19:1998;379-383.
37. Kwong K.Y., Zou Y., Day C.P., Hung M.C. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. Oncogene. 21:2002;8340-8346.
38. Larabell C.A., Torres M., Rowning B.A., Yost C., Miller J.R., Wu M., Kimelman D., Moon R.T. Establishment of the dorso-ventral axis in Xenopus embryos is presaged by early asymmetries in beta-catenin that are modulated by the Wnt signaling pathway. J. Cell Biol. 136:1997;1123-1136.
39. Lee Y.J., Swencki B., Shoichet S., Shivdasani R.A. A possible role for the high mobility group box transcription factor Tcf-4 in vertebrate gut epithelial cell differentiation. J. Biol. Chem. 274:1999;1566-1572.
40. Lee J.Y., Miraglia S., Yan X., Swartzman E., Cornell-Kennon S., Mellentin-Michelotti J., Bruseo C., France D.S. Oncology drug discovery application using the FMAT 8100 HTS system. J. Biomol. Screen. 8:2003;81-88.
41. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., Pestell R.G., Hung M.C. Beta-catenin, a novel prognostic marker for breast cancer. its roles in cyclin D1 expression and cancer progression Proc. Natl. Acad. Sci. USA. 97:2000;4262-4266.
42. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 108:2002;837-847.
43. Markowitz S.D., Dawson D.M., Willis J., Willson J.K. Focus on colon cancer. Cancer Cell. 1:2002;233-236.
44. McGovern S.L., Caselli E., Grigorieff N., Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45:2002;1712-1722.
45. Molenaar M., van de Wetering M., Oosterwegel M., Peterson-Maduro J., Godsave S., Korinek V., Roose J., Destree O., Clevers H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell. 86:1996;391-399.
46. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 275:1997;1787-1790.
47. Mulholland D.J., Cheng H., Reid K., Rennie P.S., Nelson C.C. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J. Biol. Chem. 277:2002;17933-17943.
48. Murray N.R., Davidson L.A., Chapkin R.S., Clay Gustafson W., Schattenberg D.G., Fields A.P. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J. Cell Biol. 145:1999;699-711.
49. Naishiro Y., Yamada T., Takaoka A.S., Hayashi R., Hasegawa F., Imai K., Hirohashi S. Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res. 61:2001;2751-2758.
50. Omer C.A., Miller P.J., Diehl R.E., Kral A.M. Identification of Tcf4 residues involved in high-affinity beta-catenin binding. Biochem. Biophys. Res. Commun. 256:1999;584-590.
51. Orford K., Crockett C., Jensen J.P., Weissman A.M., Byers S.W. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J. Biol. Chem. 272:1997;24735-24738.
52. Owellen R.J., Hartke C.A., Dickerson R.M., Hains F.O. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. 36:1976;1499-1502.
53. Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., Baly D., Baughman S.A., Twaddell T., Glaspy J.A.et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16:1998;2659-2671.
54. Poy F., Lepourcelet M., Shivdasani R.A., Eck M.J. Structure of a human Tcf4-beta-catenin complex. Nat. Struct. Biol. 8:2001;1053-1057.
55. Rubinfeld B., Albert I., Porfiri E., Fiol C., Munemitsu S., Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science. 272:1996;1023-1026.
56. Rubinfeld B., Robbins P., El-Gamil M., Albert I., Porfiri E., Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 275:1997;1790-1792.
57. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., Kawasoe T., Ishiguro H., Fujita M., Tokino T.et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24:2000;245-250.
58. Shirodkar S., Ewen M., DeCaprio J.A., Morgan J., Livingston D.M., Chittenden T. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell. 68:1992;157-166.
59. Shoichet S.A., Malik T.H., Rothman J.H., Shivdasani R.A. Action of the Caenorhabditis elegans GATA factor END-1 in Xenopus suggests that similar mechanisms initiate endoderm development in ecdysozoa and vertebrates. Proc. Natl. Acad. Sci. USA. 97:2000;4076-4081.
60. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA. 96:1999;5522-5527.
61. Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:1998;1130-1134.
62. Takeda U., Okada T., Takagi M., Gomi S., Itoh J., Sezaki M., Ito M., Miyadoh S., Shomura T. SF2446, new benzo[a]naphthacene quinone antibiotics. I. Taxonomy and fermentation of the producing strain, isolation and characterization of antibiotics. J. Antibiot. (Tokyo). 41:1988;417-424.
63. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:1999;422-426.
64. Toogood P.L. Inhibition of protein-protein association by small molecules. approaches and progress J. Med. Chem. 45:2002;1543-1558.
65. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P.et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 111:2002;241-250.
66. van Noort M., Clevers H. TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev. Biol. 244:2002;1-8.
67. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 80:1995;285-291.
68. Yost C., Torres M., Miller J.R., Huang E., Kimelman D., Moon R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10:1996;1443-1454.